Pharma 2026 Outlook (1/2): Maintain Market Perform
Eric Axon, CFA - Co-Head of High Yield, Head of Healthcare, CreditSights
Patrick Cunniff - Analyst, Healthcare, CreditSights
6 January 2026
Insights into CreditSights Pharma 2026 Outlook (1/2): Maintain Market Perform, including:
- Market Perform rating sustained despite revenue growth headwinds from patent losses: Consequently, pharma fundamentals remain healthy though M&A activity will drive modest leveraging trends ahead.
- Medicare price negotiations deliver 38-79% gross discounts on initial drug basket: IRA-mandated reductions take effect January 2026 with incremental impact on net pricing expectations.
- Patent expirations accelerate with $366 billion aggregate revenues at risk through 2030: Notable LOEs affect Keytruda, Eliquis, Vyndaqel requiring enhanced pipeline development and business diversification strategies.
- M&A capacity remains robust across investment-grade pharma limiting downgrade risks: Moreover, bolt-on and medium-sized transactions expected as companies address growth needs and exclusivity losses.
- Most Favored Nation pricing resolved through voluntary Medicaid reductions: Drugmaker agreements satisfy administration goals while limiting discounts to 3-11% revenue exposure business line.
Executive Summary
Credit fundamentals are expected to remain healthy despite operational headwinds from patent losses and pricing. Leverage may increase as M&A activity responds to these industry challenges in 2026.
Pharma sector anticipates 7.4% revenue growth through 2030 driven by innovative drug approvals. Consequently, growth distribution will vary significantly among companies based on product launches versus losses.
Patent expirations will accelerate materially affecting nearly all companies with notable exposure across portfolios. These losses create pressure on late-stage pipelines, commercial launches, and business development activities.
Bolt-on and medium-sized M&A transactions are anticipated as companies strengthen their late-stage pipelines.However, robust M&A capacity across the sector should limit potential downgrade risks ahead.
Moderate new issue volumes are expected with most companies refinancing their 2026 debt maturities. M&A financing will represent the primary variable affecting overall issuance volumes this year.
Fill out the below form to view the full article:
Please note that we can only respond to valid business email addresses and the interview is already available to clients.
Recently Published
Research
AllCovenant-ReviewAutosUS CR Quarterly Q1BasicLevFin-InsightsTelecommunicationsMay GMUFinancialsCreditSights-ResearchUtilitiesCase Studiesshow-homeshow-initiation page-homeMunicipalsSLRsTMTAsset Management ResourcesPharmaceuticalsJune GMUEnergyResearchGaming/LeisureWebinar Related ResourceIndustrialsPoliticsMediaUS Special Sits OutlookConsumerTariffsSpecial SituationsEuro Autos: Barbarians at the GatesCorporatePrivate CreditAerospace/DefenseU.S. Autos Expert PanelCovenantsBondsReal EstateEU Special Sits OutlookStrategyPost PetitionServicesJuly GMUESGChemicalsIranAsia in Focus 2H26ESG-HomeEmerging MarketsBanksEM OutlookOutlooks-HomeTransportationConstructionEMEA CR Quarterly Q2TechnologyInsuranceAsia in focus webinarUS CR Quarterly Q2ManufacturingEMEA CR Quarterly Q1
US CLO Weekly: BSL CLO new issuance rises to $3.7bn with Triple As 121-131bps as refinancings decline
US CLO Weekly: BSL CLO new issuance rises to $3.7bn with Triple As 121-131bps as refinancings decline
Read More
US Private Credit Monthly: PC-to-BSL moves hit exodus levels in July
US Private Credit Monthly: PC-to-BSL moves hit exodus levels in July
Read More
EMEA SS Monthly: Controversial deals, priming moves, furious creditors, and debt-for-equity swaps punctuate July
EMEA SS Monthly: Controversial deals, priming moves, furious creditors, and debt-for-equity swaps punctuate July
Read More
Euro Strategy: IG Curve Recs & Tactical Trades